Abstract:Heart growth is tightly controlled so that the heart reaches a predetermined size. Fetal heart growth occurs through cardiomyocyte proliferation, whereas postnatal heart growth involves primarily physiological cardiomyocyte hypertrophy. The Hippo kinase cascade is an important regulator of organ growth. A major target of this kinase cascade is YAP1, a transcriptional coactivator that is inactivated by Hippo kinase activity. Here, we used both genetic gain and loss of Yap1 function to investigate its role in regulating proliferative and physiologic hypertrophic heart growth. Fetal Yap1 inactivation caused marked, lethal myocardial hypoplasia and decreased cardiomyocyte proliferation, whereas fetal activation of YAP1 stimulated cardiomyocyte proliferation. Enhanced proliferation was particularly dramatic in trabecular cardiomyocytes that normally exit from the cell cycle. Remarkably, YAP1 activation was sufficient to stimulate proliferation of postnatal cardiomyocytes, both in culture and in the intact heart. A dominant negative peptide that blocked YAP1 binding to TEAD transcription factors inhibited YAP1 proliferative activity, indicating that this activity requires YAP1-TEAD interaction. Although Yap1 was a critical regulator of cardiomyocyte proliferation, it did not influence physiological hypertrophic growth of cardiomyocytes, because postnatal Yap1 gain or loss of function did not significantly alter cardiomyocyte size. These studies demonstrate that Yap1 is a crucial regulator of cardiomyocyte proliferation, cardiac morphogenesis, and myocardial trabeculation. Activation of Yap1 in postnatal cardiomyocytes may be a useful strategy to stimulate cardiomyocyte expansion in therapeutic myocardial regeneration.

Control of skeletal morphogenesis by the Hippo-YAP/TAZ pathway

Yap1 Regulates Multiple Steps of Chondrocyte Differentiation during Skeletal Development and Bone Repair

Reciprocal Inhibition of YAP/TAZ and NF-κB Regulates Osteoarthritic Cartilage Degradation

Integration of Mechanical and Chemical Signals by YAP and TAZ Transcription Coactivators.

Inactivation of Yap Oncoprotein by the Hippo Pathway is Involved in Cell Contact Inhibition and Tissue Growth Control

The Hippo pathway effectors TAZ and YAP in development, homeostasis and disease

The Hippo-YAP Pathway in Organ Size Control and Tumorigenesis: an Updated Version.

Structural and functional insights into the TEAD-YAP complex in the Hippo signaling pathway

Molecular mechanisms of the mammalian Hippo signaling pathway.

YAP-mediated regulation of the chondrogenic phenotype in response to matrix elasticity

Skeletal cell YAP and TAZ combinatorially promote bone development

YAP/TAZ for Cancer Therapy: Opportunities and Challenges (Review).

A YAP/TAZ-induced feedback mechanism regulates Hippo pathway homeostasis.

Emerging role and function of Hippo-YAP/TAZ signaling pathway in musculoskeletal disorders

YAP/TAZ for cancer therapy: Opportunities and challenges (Review)

The Regulation and Function of YAP Transcription Co-Activator

The YAP and TAZ transcription co-activators: key downstream effectors of the mammalian Hippo pathway.

Insights into the Regulation of Yap/Taz from Cellular Systems and Mouse Models

Yap1, the Nuclear Target of Hippo Signaling, Stimulates Heart Growth Through Cardiomyocyte Proliferation but Not Hypertrophy

Role of YAP/TAZ in Cell Lineage Fate Determination and Related Signaling Pathways

The Hippo Pathway Effector Proteins YAP and TAZ Have Both Distinct and Overlapping Functions in the Cell